相关实验视频

Updated: Jun 3, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

基于的CAR-NK细胞:一种用于治疗固体瘤的新策略

Qianqian Wang¹, Xin Yuan¹, Cuijuan Liu¹

¹School of Nano Technology and Nano Bionics, University of Science and Technology of China, Hefei 230026, China; CAS Key Laboratory of Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou 215123, China.

Biochemical pharmacology

|January 6, 2025

概括

基于的CAR-NK细胞通过克服CAR-T的局限性,为固体瘤治疗提供了一个有希望的解决方案. 这些工程细胞表现出有效的瘤细胞杀伤,同时降低了瘤外毒性,为改进的癌症免疫疗法铺平了道路.

科学领域:

免疫治疗是一种免疫疗法.
在瘤学瘤学.
生物技术是生物技术.

背景情况:

化学抗原受体 (CAR) -T细胞疗法在血液癌症中显示出有效性,但由于抗原稀缺和免疫抑制瘤微环境,在固体瘤中面临挑战.
CAR-NK细胞提供了一个替代方案,提供减少细胞因子释放综合征 (CRS) 和HLA独立性,但它们的固体瘤疗效是有限的.
目前使用单链可变片段 (scFvs) 的CAR设计难以有效显示,并可能导致点外瘤 (OTOT) 毒性.

研究的目的:

开发基于的CAR-NK细胞作为一种新的策略,以提高对固体瘤的疗效.
为组合疗法设计针对PD-L1,EGFR和VEGFR2的三特异性CAR-NK细胞.
与基于scFv的CAR-NK细胞相比,评估基于的CAR-NK细胞的治疗潜力和安全概况.

主要方法:

构建针对A1抗原的基于的CAR-NK92MI细胞,并评估它们对A549瘤细胞的抑制作用.
开发了三种特异性的CAR-NK92MI细胞,这些细胞配备了针对PD-L1,EGFR和VEGFR2.2的类.
在基于和基于scFv的CAR-NK92MI细胞之间对杀死活性和OTOT毒性的比较分析.

主要成果:

基于的CAR-NK92MI细胞对A549瘤细胞生长表现出显著的抑制作用.
三特异性CAR-NK92MI细胞表现出与基于scFv的CAR-NK92MI具有相似的瘤细胞杀伤活性.
与基于scFv的对应物相比,基于的CAR-NK92MI细胞显示出较低的OTOT毒性.

结论:

基于的CAR-NK细胞代表了固体瘤免疫疗法的有希望的进步.
使用低分子量可以实现多重定位和改进安全配置文件.
基于的工程CAR-NK细胞提供了一种可行的替代方案,以克服固体瘤中CAR-T细胞治疗的局限性.

关键词:

亲密关系 (Affinity) 是一种关系.化学抗原受体的化学抗原受体在 NK92MI 细胞中.目标外的毒性目标外的毒性这是一种类.固体瘤是一个固体瘤.运输安全局 (TSA) 在

更多相关视频

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...